Drug Eluting Stents (DES) Pipeline Technology and Market Forecasts to 2016

GlobalData, December 2009, Pages: 58

Drug Eluting Stents (DES) Pipeline Technology and Market Forecasts to 2016

Summary

Our “Drug Eluting Stents (DES) Pipeline Technology and Market Forecasts to 2016” report is an essential source of information and analysis on the global Drug Eluting Stents (DES) market. The report identifies the key trends shaping and driving the dynamism in the global Drug Eluting Stents (DES) market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Drug Eluting Stents (DES) sector.

Scope

- Annualized global Drug Eluting Stents (DES) market revenues data from 2001 to 2008, forecast forward for 7 years to 2015. Updated company shares data for 2008.
- Analysis and review of the key events and milestones that will impact the future of the global Drug Eluting Stents (DES) market. Each trend independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends.
- Insightful review of key industry drivers, restraints and challenges which are likely to impact the global Drug Eluting Stents (DES) market in the long run.
- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies. Key companies include Cordis Corporation, - Boston Scientific, Medtronic, and Abbott Laboratories.
- Comprehensive analysis of the most likely developments expected to bring a shift to the market positions of the leading manufacturers.
- The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Our team of industry experts.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global Drug Eluting Stents (DES) market.
- Identify key players best positioned to take advantage of the emerging market opportunities by developing insight on the prevalent and anticipated competitive landscape.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Drug Eluting Stents (DES) market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Support your go/non-go dilemma by identifying the markets that are least competitive and present significant opportunities for innovation and growth.
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

1 Table Of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
3 Global DES Market : Market Characterization
3.1 Overview
3.2 DES, Revenue ($ m), Global, 2002 - 2009
3.3 DES, Revenue ($ m), Global, 2009 - 2016
3.4 DES: Market Dynamics
3.4.1 Market Drivers
3.4.1.1 Increasing Prevalence of Coronary Artery Disease to Drive DES Market
3.4.1.2 Rise in Obesity and Increasing Aging Population Worldwide to Advance the Market
3.4.1.3 Innovation to Drive the Market
3.4.1.4 Reduction in Re-Interventions in Diabetics- A Population Highly Susceptible To Restenosis to Boost Sales
3.4.1.5 High Reimbursement Coverage to Boost Adoption
3.4.1.6 Minimally Invasive Surgery to Play Vital Role in Market Development
3.4.2 Market Restraints
3.4.2.1 High Cost of DES to Hamper the Market Growth
3.4.2.2 Side effects like Late-stent Thrombosis and Requirement of Prolonged Dual Anti-platelet Therapy with DES Use to Affect Market Expansion
3.4.2.3 Negative Publicity Related to Stent Market Have Affected the Usage of DES
3.4.2.4 Alternative Treatment Options Creating a Threat to the Usage of Coronary Stents
3.5 DES: Perception Analysis
3.6 DES: Opportunities and Unmet Need
3.7 Key Takeaway
4 Global DES Market : Competitive Assessment
4.1 Overview
4.2 Strategic Competitive Assessment
4.3 Company Shares 2009
4.3.1 Cordis Corporation (Johnson & Johnson)
4.3.2 Boston Scientific
4.3.3 Medtronic
4.3.4 Abbott Laboratories
4.3.5 Others
4.4 Product Profiles of the Major Marketed Products in the DES Market
4.4.1 Cypher
4.4.1.1 Overview
4.4.1.2 Efficacy
4.4.1.3 Safety Profile
4.4.1.4 Pricing
4.4.1.5 Clinical Study Details
4.4.2 Taxus
4.4.2.1 Overview
4.4.2.2 Efficacy
4.4.2.3 Safety
4.4.2.4 Pricing
4.4.2.5 Clinical Study Details
4.4.3 Endeavor
4.4.3.1 Overview
4.4.3.2 Efficacy
4.4.3.3 Safety Profile
4.4.3.4 Pricing
4.4.3.5 Clinical Study Details
4.4.4 Xience/Promus
4.4.4.1 Overview
4.4.4.2 Efficacy
4.4.4.3 Safety Profile
4.4.4.4 Pricing
4.4.4.5 Clinical Study Details
4.5 Key Takeaway
5 Global DES Market: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 DES - Pipeline by Clinical Phase of Development
5.4 Profiles of Promising Devices in Clinical Development
5.4.1 Endeavor Resolute
5.4.1.1 Overview
5.4.1.2 Efficacy
5.4.1.3 Safety
5.4.1.4 Clinical Study Details
5.4.2 VESTAsync
5.4.2.1 Overview
5.4.2.2 Efficacy
5.4.2.3 Safety
5.4.2.4 Clinical Study Details
5.4.3 Nobori Stent
5.4.3.1 Overview
5.4.3.2 Efficacy
5.4.3.3 Safety
5.4.3.4 Clinical Study Details
5.4.4 XIENCE NANO
5.4.4.1 Overview
5.4.4.2 Efficacy
5.4.4.3 Safety
5.4.4.4 Clinical Study Details
5.5 DES Market: List of Pipeline Products
5.6 Key Takeaway
6 Global DES Market : Implications for Future Market Competition
6.1 Strategic Competitor Assessment
7 Global DES Market: Emerging Companies
7.1 Introduction
8 Appendix
8.1 Definitions
8.1.1 Drug Eluting Stents (DES)
8.2 Research Methodology
8.3 Secondary Research
8.4 Primary Research
8.5 Models
8.6 Forecasts
8.7 Expert Panels
8.8 Consulting
8.9 Contact Us
8.10 Disclaimer

Executive Summary

1.1 List of Tables
Table 1: DES, Revenue ($ m), Global, 2002 - 2009 10
Table 2: DES, Revenue ($ m), Global, 2009 - 2016 11
Table 3: Company Shares, US, 2009 22
Table 4: CYPHER Clinical Study Details - I 25
Table 5: CYPHER Clinical Study Details - II 25
Table 6: CYPHER Clinical Study Details - III 26
Table 7: Endeavor Clinical Study Details - I 29
Table 8: Endeavor Clinical Study Details - II 30
Table 9: Endeavor Clinical Study Details - III 30
Table 10: XIENCE Safety Data 31
Table 11: XIENCE Clinical Study Details - I 32
Table 12: XIENCE Clinical Study Details - II 32
Table 13: XIENCE Clinical Study Details - III 33
Table 14: XIENCE Clinical Study Details - IV 33
Table 15: XIENCE Clinical Study Details - V 34
Table 16: XIENCE Clinical Study Details - VI 34
Table 17: Endeavor Resolute Clinical Findings - I 41
Table 18: Endeavor Resolute Clinical Findings - II 42
Table 19: NOBORI Stent Clinical Trial Details 45
Table 20: DES Pipeline Product Summary - I 47
Table 21: DES Pipeline Product Summary - II 48
Table 22: DES Emerging Companies and Pipeline Products - I 52
Table 23: DES Emerging Companies and Pipeline Products - II 53

Customers who bought this item also bought

• Coronary Stents - Global Strategic Business Report
• Interventional Cardiology - Global Strategic Business Report
• European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries)
• Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability
• Global Coronary Stent Market Report
• Innovations in Cardiovascular Disease Management: Latest Surgical Procedures, Drugs and Medical Devices
• European Markets for Interventional Cardiology 2009 (15 Countries)
• Global Coronary Stent Market Report: 2010 Edition
• Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011
• Western European Markets for Peripheral Vascular Stents and AAA Stent-Grafts